Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 14/20 | 0.72 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463458 | 0.84 | AR (1.00) | AR | |
| SCHEMBL4463462 | 0.84 | AR (1.00) | AR | |
| SCHEMBL13676633 | 0.81 | AR (0.49) | ARCYP11B2 | |
| SCHEMBL13676583 | 0.81 | AR (0.49) | ARCYP11B2TRPV4 | |
| SCHEMBL14456537 | 0.76 | AR (0.57) | AR | |
| SCHEMBL4299688 | 0.73 | AR (0.61) | ARCYP11B2TRPV4 | |
| SCHEMBL24187113 | 0.73 | AR (0.59) | AR | |
| SCHEMBL5017575 | 0.73 | USP14 (0.45) | AR | |
| SCHEMBL24295264 | 0.73 | USP14 (0.45) | AR | |
| Hydrochloric Acid SCHEMBL30994859 | 0.73 | AR (0.60) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836202-B1 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ACADIA PHARM INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20090270449-A1 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SCHLIENGER NATHALIE | 2009-10-29 | — | — | US | disclosed |
| US-7585877-B2 | Aminophenyl derivatives as selective androgen receptor modulators | ACADIA PHARMACEUTICALS, INC. | 2009-09-08 | — | — | US | disclosed |
| US-7585877-B2 | Aminophenyl derivatives as selective androgen receptor modulators | ACADIA PHARMACEUTICALS, INC. | 2009-09-08 | — | — | US | disclosed |
| EP-1660455-B1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2006076317-A9 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ACADIA PHARM INC (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007092400-A1 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| US-6933311-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES | 2005-05-26 | — | — | US | disclosed |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | AR 267/4885CYP11B2 2139/4885TRPV4 31/4885 |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, TMEM109, VIPR1 | AR 245/4885CYP11B2 2169/4885TRPV4 24/4885 |
| US-20090270449-A1 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, ESRRA | AR 1/4885CYP11B2 31/4885TRPV4 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.